Navigation Links
Clinical Trial by Licensee Does Not Meet Primary Endpoint
Date:7/30/2009

PASADENA, Calif., July 30 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today announced its licensee, BioMS Medical Corp., and Eli Lilly and Company reported that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences between dirucotide and placebo on the secondary endpoints of the study. Lilly and BioMS also announced that they would discontinue ongoing clinical trials and review available data.

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug, dirucotide, if it reaches the market.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "We are obviously disappointed by the results and look forward to further announcements from BioMS and Lilly regarding their future plans for this approach to treating SPMS."

AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, the uncertainties of clinical trial results, AutoImmune's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in AutoImmune's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission in the section entitled "Risk Factors."


'/>"/>
SOURCE AutoImmune Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Are imaging features of hepatic angiomyolipoma related to its clinical setting?
2. Summa Health System Creates Quick Win With Their Caregiver Community By Implementing Sentillions Clinical Workstation Solution
3. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence at the American Podiatric Medical Association (APMA) Annual Scientific Meeting in Toronto, Canada
4. HOWARU(R) Protect Clinically Shown to Reduce the Incidence and Severity of Cold and Flu Symptoms in Children
5. Sunshine Heart Provides C-Pulse U.S. Clinical Update
6. QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System
7. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results
8. Alexza to Announce 2009 Second Quarter Financial Results and Update Its Clinical Pipeline Status on Wednesday, August 5, 2009
9. Male Fertility Supplement Improves Sperm Quality & Motility in Clinical Study
10. Lutonix, Inc. Announces First Patient Enrollments in Three Separate Clinical Trials
11. Cardiorobotics Closes $11.6M Series A Financing to Advance Clinical Development of Snake Robot for Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... Prairie, MN (PRWEB) , ... May 31, 2016 , ... ... from the American Association for Laboratory Accreditation (A2LA) to include ISO 594-1 and ISO ... most common means of achieving a leak-free connection between two medical devices (e.g. a ...
(Date:5/31/2016)... Greifensee, Switzerland (PRWEB) , ... May 31, 2016 , ... ... adopt this model in their laboratories as well. However, laboratories have different challenges compared ... many benefits of lean operations in the lab, METTLER TOLEDO has developed the ...
(Date:5/31/2016)... ... , ... In his latest video, renowned AstroNumerologist Jesse Kalsi ... presidential candidate Donald Trump as an example, Kalsi describes the way AstroNumerology conveys ... adding numbers up,” says Kalsi. “It is about looking at each individual number, ...
(Date:5/31/2016)... ... May 31, 2016 , ... Phynd Technologies, Inc. announced recently the ... – Houston, TX and Shore Medical Center – Somers Point, NJ. The new clients ... EHR solutions, demonstrating the breadth of Phynd’s solution and its interoperability. , Houston Methodist ...
(Date:5/31/2016)... ... May 31, 2016 , ... Dr. Charles A. Ditta attained his Doctor of ... the class of 1986, where he graduated in the top ten percentile of his ... Livingston since 1989. He has been a member in good standing for thirty years ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 26, 2016   Change Healthcare , ... network solutions and technology-enabled services designed to ... into a strategic channel partnership with SourceMed, ... solutions and revenue cycle management services that ... rehabilitation clinics to optimize revenue, operational efficiency ...
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
(Date:5/25/2016)... Deutschland und GERMANTOWN, Maryland , ... Zusammenarbeit mit Therawis bedient dringenden ...   QIAGEN N.V. (NASDAQ: ... bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics ... die Onkologie eingegangen zu sein. Ein erstes Projekt ...
Breaking Medicine Technology: